Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

21.11 +0.16 (+0.76%)
Streaming Delayed Price Updated: 1:26 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
1 of Wall Street’s Favorite Stock to Target This Week and 2 We Find Risky
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
3 Low-Volatility Stocks with Questionable Fundamentals
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Topics Supply Chain
Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. 
Via StockStory
Topics Stocks World Trade
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit World Trade
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Earnings Outlook For Amphastar Pharma
 
Via Benzinga
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory
Topics ETFs Stocks World Trade
1 Healthcare Stock on Our Buy List and 2 to Approach with Caution
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – An Undervalued Stock Worth Considering
AMPH ASTAR PHARMACEUTICALS (NASDAQ:AMPH) presents an undervalued opportunity with strong profitability, reasonable financial health, and historical growth, making it a candidate for value investors. 
Via Chartmill
1 Healthcare Stock with Solid Fundamentals and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
3 Value Stocks with Questionable Fundamentals
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – An Undervalued Stock Worth Considering
AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) is an undervalued stock with strong profitability, reasonable financial health, and an attractive valuation, making it a candidate for value investors. 
Via Chartmill
3 Russell 2000 Stocks with Questionable Fundamentals
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
3 Small-Cap Stocks Walking a Fine Line
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports,... 
Via StockStory
Topics Artificial Intelligence Government Stocks
Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – A Potentially Undervalued Stock Worth Watching
AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) offers strong profitability and an undervalued stock price, making it a candidate for value investors. Check the full analysis for details. 
Via Chartmill
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 Sales Targets
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74... 
Via StockStory
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential 
Via Chartmill
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is an undervalued gem with solid fundamentals.
Uncover the potential of AMPHASTAR PHARMACEUTICALS IN, an undervalued stock. NASDAQ:AMPH maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
2 Reasons to Like AMPH and 1 to Stay Skeptical
What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. This was partly due to its softer quarterly results... 
Via StockStory
Topics Supply Chain
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), an undervalued stock with good fundamentals.
Take a closer look at AMPHASTAR PHARMACEUTICALS IN , a remarkable value stock. NASDAQ:AMPH excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
Amphastar's Q4 sales grew 20% to $186.5M, missing estimates. Primatene MIST surpassed $100M in annual sales, while Baqsimi saw strong growth. 
Via Benzinga
Amphastar: Earnings Miss, Margins Drop
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.